Serotonin syndrome is a drug-induced toxidrome caused by excess serotonergic activity at central nervous system (CNS) receptors, most commonly resulting from combinations of drugs that together produce more serotonergic stimulation than any single agent alone. It is not an idiosyncratic reaction but a predictable pharmacodynamic consequence of excessive 5-HT receptor activation. The ability to recognize serotonin syndrome, distinguish it from its principal mimics, apply the correct diagnostic criteria, and initiate appropriate management is a mandatory clinical competency for any prescriber using serotonergic drugs.
The pathophysiology of serotonin syndrome involves simultaneous overstimulation of two 5-HT receptor subtypes in the CNS. Excess activation of postsynaptic 5-HT1A receptors in the brainstem and spinal cord produces autonomic instability through effects on cardiovascular and thermoregulatory centers, and contributes to the neuromuscular hyperactivity through disinhibition of motor pathways. Excess activation of postsynaptic 5-HT2A receptors on pyramidal neurons of the cerebral cortex produces the altered mental status component and, through actions at spinal cord interneurons, the characteristic neuromuscular features of clonus and hyperreflexia. Understanding this dual-receptor basis explains why cyproheptadine, a 5-HT2A antagonist, is used in treatment, and why it is not sufficient to simply reduce serotonin at one receptor subtype: full resolution requires reduction of excess serotonergic tone broadly.1
The clinical presentation of serotonin syndrome is defined by a triad of altered mental status, autonomic instability, and neuromuscular abnormalities. Altered mental status ranges from mild agitation and anxiety to delirium and coma. Autonomic instability includes tachycardia, diaphoresis, mydriasis, and either hypertension or hypotension; hyperthermia is a cardinal sign and its severity correlates with outcome. Neuromuscular abnormalities are the most diagnostically specific features: clonus (spontaneous, inducible, and ocular), hyperreflexia, myoclonus, and tremor. In severe cases, muscle rigidity can develop; however, unlike neuroleptic malignant syndrome (NMS), where rigidity is the dominant and earliest neuromuscular finding, in serotonin syndrome rigidity is a late and severe finding, preceded by hyperreflexia and clonus. This temporal sequence is the most clinically useful feature distinguishing the two syndromes.2
The Hunter Criteria are the preferred diagnostic tool for serotonin syndrome, having replaced the older Sternbach criteria due to superior sensitivity and specificity. Diagnosis requires a serotonergic agent in the history plus one of the following: spontaneous clonus; inducible clonus with agitation or diaphoresis; ocular clonus with agitation or diaphoresis; tremor with hyperreflexia; or hypertonia with temperature above 38 degrees Celsius plus ocular clonus or inducible clonus. The Hunter Criteria have a sensitivity of approximately 84% and specificity of 97% for serotonin toxicity when validated against a toxicologist gold standard. The key diagnostic discriminator from NMS is the neuromuscular pattern: clonus and hyperreflexia (serotonin syndrome) versus lead-pipe rigidity and bradyreflexia (NMS). From anticholinergic toxicity, the presence of bowel sounds and diaphoresis distinguishes serotonin syndrome (anticholinergic toxicity produces absent bowel sounds and dry skin).3
Severity grading guides management intensity. Mild serotonin syndrome manifests as tachycardia, diaphoresis, mydriasis, intermittent tremor, and myoclonus without hemodynamic compromise or significant hyperthermia; these patients may be managed with discontinuation of the offending agent(s) and supportive care. Moderate severity adds hyperthermia (up to 40 degrees Celsius), hyperreflexia, inducible clonus, and agitation requiring sedation. Severe serotonin syndrome is characterized by temperature exceeding 41 degrees Celsius, severe muscle rigidity, rhabdomyolysis, metabolic acidosis, renal failure, respiratory failure, and disseminated intravascular coagulation (DIC). Management of moderate to severe serotonin syndrome requires immediate discontinuation of all serotonergic agents, aggressive intravenous benzodiazepines for agitation and muscular hyperactivity (which also reduces heat production from muscle contraction), and active cooling. Cyproheptadine, a first-generation antihistamine with potent 5-HT2A antagonist properties, is administered orally or via nasogastric tube at 12 mg loading dose followed by 2 mg every 2 hours to effect, with a maximum of 32 mg per day; it is not available parenterally.4
Serotonin syndrome: rapid onset (hours), hyperreflexia, clonus, diaphoresis, bowel sounds present, caused by serotonergic drug combinations. Neuroleptic malignant syndrome (NMS): slower onset (days to weeks), lead-pipe rigidity, bradyreflexia, no clonus, caused by dopamine antagonist agents. Anticholinergic toxicity: absent bowel sounds, dry skin, urinary retention, no clonus; caused by muscarinic antagonists. Temperature elevation and hemodynamic instability occur in all three but the neuromuscular pattern is the key discriminator. In NMS, creatine kinase (CK) is typically markedly elevated early; in serotonin syndrome, CK elevation occurs later and reflects rhabdomyolysis from sustained muscle rigidity rather than primary muscle injury.
The drug combinations most reliably producing clinically significant serotonin syndrome are those pairing an irreversible monoamine oxidase inhibitor (MAOI) with any serotonin-releasing or reuptake-blocking agent. MAOI plus meperidine (pethidine) is a classic and frequently lethal combination: meperidine has serotonin reuptake inhibitor properties in addition to its opioid activity, producing rapid-onset severe serotonin syndrome. MAOI plus dextromethorphan (a common over-the-counter antitussive with potent SERT inhibition) produces a similar picture. MAOI plus any SSRI or SNRI is absolutely contraindicated. Other high-risk combinations include SSRI or SNRI plus tramadol (a weak SNRI with opioid activity), linezolid (an antibiotic with MAOI properties), intravenous methylene blue (a potent MAOI used for methemoglobinemia), or high-dose fentanyl in serotonin-sensitized patients. St. John's wort, through hyperforin-mediated SERT inhibition, can precipitate serotonin syndrome when combined with SSRIs or MAOIs.1
Monoamine oxidase inhibitors (MAOIs) were among the first antidepressants discovered and remain clinically relevant today, both as antidepressants of last resort in treatment-resistant depression and as the drug class most responsible for life-threatening serotonin syndrome when used improperly. Their pharmacology involves irreversible enzyme inactivation that outlasts the drug's pharmacokinetic elimination by weeks, producing a pharmacodynamic footprint that demands understanding of enzyme regeneration kinetics rather than conventional half-life thinking.
The classic irreversible MAOIs used as antidepressants are phenelzine and tranylcypromine. Both form stable covalent bonds with the flavin cofactor of MAO-A and MAO-B, irreversibly inhibiting both isoforms. Phenelzine is a hydrazine derivative that undergoes acetylation and oxidative metabolism; its irreversible inhibition of MAO-A means that serotonin and norepinephrine accumulate in presynaptic neurons and synaptic clefts, producing antidepressant effects. Tranylcypromine is structurally related to amphetamine and has some direct sympathomimetic properties in addition to MAO inhibition. Neither agent has selectivity between MAO-A and MAO-B at therapeutic doses. Both require dietary tyramine restriction and carry the highest risk of hypertensive crisis and serotonin syndrome among the MAOIs. The antidepressant effect of irreversible MAOIs is typically superior to that of SSRIs in atypical depression (characterized by mood reactivity, hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity), which is why these agents retain a clinical role despite their interaction burden.5
Selegiline is a selective irreversible MAO-B inhibitor at low doses (up to 10 mg per day orally), used primarily for Parkinson disease as an adjunct to levodopa. At low doses, MAO-B inhibition does not substantially inhibit tyramine metabolism in the gut (which is mediated predominantly by MAO-A), so dietary restrictions are not required at the standard Parkinson dose. At higher doses or with the transdermal formulation (selegiline patch at 9 mg/24 hr and above), MAO-A inhibition begins to occur, and dietary tyramine restriction becomes necessary. The transdermal formulation delivers selegiline systemically while bypassing gut first-pass metabolism, achieving CNS concentrations that produce antidepressant effects; it is FDA-approved for major depressive disorder (MDD). Even at the 6 mg/24 hr starting dose of the transdermal formulation, the prescribing information recommends dietary tyramine restriction as a precaution, though the tyramine interaction risk is substantially lower than with oral irreversible MAOIs.6
The tyramine interaction is one of the most mechanistically instructive drug-food interactions in clinical pharmacology. Under normal circumstances, dietary tyramine absorbed from the gut is efficiently metabolized by MAO-A in the intestinal mucosa and liver during first-pass metabolism before entering the systemic circulation. Foods rich in tyramine include aged cheeses, cured and fermented meats, fermented soy products, draft beer, and wine. When MAO-A is irreversibly inhibited, dietary tyramine escapes first-pass catabolism and enters the systemic circulation. Tyramine is a substrate for the norepinephrine transporter (NET) and enters adrenergic nerve terminals via NET, where it acts as an indirect sympathomimetic: it displaces norepinephrine from vesicles into the cytoplasm and from there into the synaptic cleft, producing massive norepinephrine release. The resulting sympathetic surge causes acute, severe hypertension (hypertensive crisis), which can cause hemorrhagic stroke, aortic dissection, or myocardial infarction. Treatment of the acute hypertensive crisis is with intravenous phentolamine (a non-selective alpha-adrenergic antagonist) or sublingual nifedipine.7
Aged and fermented cheeses (tyramine content high and variable; fresh cheeses such as ricotta and cottage cheese are safe). Cured, fermented, or smoked meats: salami, pepperoni, summer sausage, smoked fish. Fermented soy: soy sauce, miso, tempeh, tofu (in large quantities). Draft and unpasteurized beer. Red wine, especially Chianti. Concentrated yeast extracts (Marmite, Vegemite). Broad (fava) beans contain DOPA, a tyramine precursor. The tyramine content of specific foods varies with aging and fermentation conditions; providing the patient with a comprehensive written list and reinforcing it at every visit is mandatory practice when prescribing irreversible MAOIs.
Moclobemide is a reversible inhibitor of MAO-A (RIMA) that differs in a clinically important way from irreversible MAOIs in its clinical safety profile. Because the binding of moclobemide to MAO-A is competitive and reversible, dietary tyramine can displace the drug from the enzyme, allowing residual MAO-A activity to metabolize tyramine even while the drug is present. This means that the tyramine interaction, while not entirely absent, is substantially attenuated relative to irreversible MAOIs, and strict dietary restriction is generally not required at therapeutic doses, though large tyramine loads (equivalent to a very large quantity of aged cheese) should still be avoided. Moclobemide has a short half-life (approximately 2 hours) and no active metabolites; MAO-A function recovers within 24 hours of stopping the drug. The washout before switching from moclobemide to another serotonergic drug is therefore only 24 hours, rather than the 14 days required after an irreversible MAOI.8 Moclobemide is not approved in the United States but is widely used in Europe and elsewhere for depression and social anxiety disorder.6
After stopping an irreversible MAOI (phenelzine, tranylcypromine): wait 14 days before starting any SSRI, SNRI, TCA, meperidine, dextromethorphan, tramadol, or other serotonergic agent. Enzyme regeneration requires 2 weeks.
After stopping most SSRIs or SNRIs before starting an irreversible MAOI: wait 14 days. This allows SERT-blocking drug to clear and prevents serotonin syndrome.
After stopping fluoxetine before starting an irreversible MAOI: wait 5 weeks. Norfluoxetine's half-life extends effective SERT blockade well beyond the parent drug's clearance.
After stopping moclobemide: wait 24 hours before starting another serotonergic drug (reversible binding, rapid recovery).
After stopping an irreversible MAOI before starting moclobemide: wait 14 days (MAO-A must regenerate before a competitive inhibitor has meaningful activity).
Triptans are selective 5-HT1B and 5-HT1D receptor agonists developed specifically for the acute treatment of migraine with or without aura and cluster headache. They do not prevent migraine and are not analgesics in the conventional sense; rather, they act on the specific pathophysiological mechanisms of migraine by targeting the cranial vasculature and the trigeminal nociceptive system. Understanding their mechanism explains both their efficacy and their cardiovascular risks.
Triptans produce their antimigraine effect through three complementary mechanisms mediated by 5-HT1B and 5-HT1D receptor agonism. First, 5-HT1B receptor activation on cranial vessel smooth muscle produces vasoconstriction of meningeal and dural vessels, reducing the distension of perivascular pain fibers that contributes to migraine pain. Second, 5-HT1D receptor activation on presynaptic trigeminal nerve terminals inhibits the release of neuropeptides including calcitonin gene-related peptide (CGRP), substance P, and neurokinin A from trigeminal afferents, reducing neurogenic inflammation in the meningeal vasculature. Third, 5-HT1B and 5-HT1D receptors on neurons in the trigeminal nucleus caudalis in the brainstem mediate central inhibition of nociceptive signal transmission, reducing second-order neuronal activation that underlies central sensitization. The relative contribution of these three mechanisms to clinical antimigraine efficacy remains debated, but the central mechanism has gained importance following evidence that triptans can abort migraine even when administered after the vasodilatory phase has resolved.9
Individual triptans differ substantially in lipophilicity, oral bioavailability, speed of onset, half-life, route of administration availability, and CNS penetration. Sumatriptan is the prototypical and most extensively studied triptan; it has low oral bioavailability (approximately 14%) due to first-pass metabolism, a short half-life of approximately 2 hours, and is available in oral, subcutaneous, intranasal, and transdermal formulations. The subcutaneous formulation achieves the fastest onset (relief within 10 minutes) and is the treatment of choice for severe attacks. Rizatriptan and eletriptan have higher oral bioavailability and faster onset than sumatriptan tablets. Naratriptan and frovatriptan are slower in onset but have longer half-lives (frovatriptan approximately 26 hours), making them useful for prolonged or menstrually related migraine attacks where duration of protection is more important than speed.10 Zolmitriptan and almotriptan have CNS penetration superior to sumatriptan, which may contribute to efficacy against central sensitization.11
The principal cardiovascular concern with triptans is coronary vasoconstriction through 5-HT1B receptors expressed in coronary smooth muscle. In vessels with normal endothelium, this effect is modest; in vessels with endothelial dysfunction or established atherosclerosis, triptan-induced coronary vasoconstriction can cause ischemia. Triptans are therefore contraindicated in patients with established coronary artery disease (CAD), a history of myocardial infarction, Prinzmetal angina, uncontrolled hypertension, and stroke or transient ischemic attack. They are also contraindicated in hemiplegic migraine and basilar-type migraine due to the potential for additional vasoconstriction in areas of already-compromised perfusion. A practical concern is that a substantial proportion of migraine patients have cardiovascular risk factors; all patients should have a cardiovascular risk assessment before triptan prescription. Triptans should not be combined with ergotamines within 24 hours of each other due to additive vasoconstriction risk; they should not be combined with MAOIs because most triptans are metabolized by MAO-A, and MAOI co-administration raises triptan plasma levels substantially while also increasing the serotonergic stimulation.11
There has been regulatory and clinical concern about combining triptans with SSRIs or SNRIs potentially causing serotonin syndrome. The American Headache Society reviewed this issue and concluded that the risk of true serotonin syndrome from triptan plus SSRI combinations at therapeutic doses is extremely low, and that the clinical benefit of treating migraine in patients on antidepressants outweighs the theoretical risk. The concern arose partly from an FDA alert in 2006 that was based on mechanistic reasoning rather than case evidence. This does not eliminate the need for clinical judgment: patients should be counseled to report any symptoms of the serotonin toxidrome, and the combination should be used cautiously in patients already at the higher end of serotonergic drug burden. The absolute contraindication remains MAOI plus triptan.
Buspirone and the 5-HT3 antagonists represent two pharmacologically distinct applications of serotonin receptor targeting that differ in mechanism from the SSRI/SNRI class: buspirone acts as a partial agonist at 5-HT1A receptors to produce anxiolytic effects without the dependence liability of benzodiazepines, while 5-HT3 antagonists block the ionotropic serotonin receptor on vagal afferents and in the area postrema to produce antiemetic effects. Neither class produces antidepressant effects through SERT blockade.
Buspirone is a member of the azapirone class of anxiolytics and acts as a high-affinity partial agonist at 5-HT1A receptors in the limbic system and raphe nuclei. As a partial agonist, buspirone activates 5-HT1A receptors but with lower intrinsic efficacy than serotonin itself; in the limbic system where serotonergic tone may be elevated in anxiety, it acts functionally as a partial antagonist, reducing excess 5-HT1A-mediated anxiety. Buspirone also has moderate affinity as a D2 receptor partial agonist, which may contribute to its calming effect without producing sedation or impaired psychomotor function. The absence of GABA-A receptor activity explains why buspirone has no anticonvulsant, muscle-relaxant, or sedative properties, does not cause physical dependence, and has no cross-tolerance with benzodiazepines. This last property is clinically important: buspirone will not suppress benzodiazepine withdrawal symptoms, and patients switched from a benzodiazepine to buspirone for anxiety must be tapered off the benzodiazepine separately.12
The onset of buspirone's anxiolytic effect is slow, typically requiring 2 to 4 weeks of continuous treatment, which is in stark contrast to the immediate anxiolytic effect of benzodiazepines. This slow onset is the primary practical disadvantage of buspirone and the most common reason for patient dissatisfaction and premature discontinuation. The mechanism underlying the delay parallels that of SSRIs: acute 5-HT1A agonism at somatodendritic autoreceptors in the raphe reduces serotonergic neuron firing, partially counteracting the anxiolytic limbic 5-HT1A stimulation. With continued exposure, these autoreceptors desensitize, allowing the limbic 5-HT1A effect to predominate. Buspirone is metabolized extensively by CYP3A4 to the active metabolite 1-pyrimidinylpiperazine (1-PP), which contributes to its alpha-2 adrenergic antagonist activity. Grapefruit juice inhibits intestinal CYP3A4 and can increase buspirone plasma concentrations by 2 to 9-fold; patients should avoid grapefruit juice during buspirone therapy. CYP3A4 inducers such as rifampin dramatically reduce buspirone levels; CYP3A4 inhibitors such as itraconazole or erythromycin substantially increase them.12
The 5-HT3 antagonist class includes ondansetron, granisetron, dolasetron, and palonosetron, all of which block the ionotropic 5-HT3 receptor on vagal afferent neurons in the gut and on neurons in the area postrema (chemoreceptor trigger zone) of the brainstem. Chemotherapy agents and radiation release serotonin from enterochromaffin (EC) cells of the small intestinal mucosa; this serotonin activates vagal 5-HT3 receptors that relay the emetic signal to the brainstem vomiting center. The area postrema, lying outside the blood-brain barrier (BBB) as a circumventricular organ, is also directly activated by circulating emetogenic substances. 5-HT3 antagonists block both peripheral and central components of this reflex, producing highly effective prevention of acute chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). Palonosetron is distinguished from the other agents by substantially higher 5-HT3 receptor binding affinity (approximately 30-fold greater than ondansetron) and a longer half-life (approximately 40 hours versus 3–5 hours for ondansetron), making it more effective for prevention of delayed CINV.13
Ondansetron causes dose-dependent QTc prolongation through hERG potassium channel blockade, with the FDA recommending against single intravenous doses exceeding 32 mg and advising caution in patients with electrolyte abnormalities (hypokalemia, hypomagnesemia), congenital long QT syndrome, or concomitant use of other QTc-prolonging drugs. The 32 mg single IV dose was removed from the approved labeling following a safety review demonstrating QTc prolongation at that dose. In most clinical settings, ondansetron 4–8 mg IV or oral doses carry an acceptable risk-benefit profile, but electrocardiogram monitoring is warranted in high-risk patients. Granisetron and palonosetron have lower QTc risk than ondansetron at standard doses and may be preferred in patients with known QT prolongation risk factors.
Vortioxetine represents a pharmacological approach to antidepressant treatment that goes substantially beyond simple SERT blockade. By combining serotonin transporter inhibition with direct modulation of multiple serotonin receptor subtypes, vortioxetine achieves a more nuanced pattern of serotonergic modulation that translates into a distinct clinical profile, most prominently including cognitive benefits that are not consistently observed with SSRIs or SNRIs. Understanding its multimodal mechanism requires familiarity with the receptor pharmacology covered in the first module of this chapter.
Vortioxetine has five distinct pharmacological activities: it inhibits SERT with high affinity (its primary mechanism, shared with SSRIs), acts as a partial agonist at 5-HT1A receptors (an activity shared with buspirone and relevant to the autoreceptor desensitization sequence), acts as a partial agonist at 5-HT1B receptors (modulating terminal serotonin release), and acts as an antagonist at 5-HT3 and 5-HT7 receptors. The 5-HT3 antagonism has two consequences: it reduces the nausea that would otherwise result from elevated synaptic serotonin acting on 5-HT3 receptors, which may explain vortioxetine's lower nausea burden compared to SSRIs at therapeutic doses despite high SERT occupancy, and it modulates cholinergic and histaminergic interneuron activity in the cortex and hippocampus in ways that are thought to contribute to the drug's cognitive effects. The 5-HT7 antagonism blocks receptors on GABAergic interneurons, disinhibiting glutamatergic pyramidal neurons and increasing cortical network activity associated with cognitive processing.14
The cognitive benefit of vortioxetine has been evaluated in randomized controlled trials using validated cognitive batteries and has been observed to be independent of its antidepressant effect, suggesting that the cognitive improvement is not simply a consequence of mood improvement. The FOCUS trial demonstrated cognitive improvements in attention, speed of processing, and executive function in depressed patients treated with vortioxetine relative to placebo, with a magnitude of effect exceeding that seen with SSRIs in similar populations. The underlying mechanism is believed to involve the combination of 5-HT3 antagonism increasing acetylcholine release in the prefrontal cortex and hippocampus (supporting working memory and attention), 5-HT7 antagonism disinhibiting cortical glutamatergic neurons (supporting learning and memory consolidation), and increased serotonergic tone generally. This cognitive profile makes vortioxetine particularly attractive for patients with major depressive disorder (MDD) in whom cognitive dysfunction is a prominent or disabling feature.15
Vortioxetine's absorption, distribution, metabolism, and excretion (ADME) profile has several clinically relevant features. It is well absorbed orally with bioavailability of approximately 75%, unaffected by food. Protein binding is high (approximately 98%). It is extensively metabolized by CYP2D6 (the primary route), CYP3A4/5, CYP2C19, and other hepatic enzymes, with all metabolites pharmacologically inactive. The half-life is approximately 66 hours, permitting once-daily dosing and providing some tolerance of missed doses. In CYP2D6 poor metabolizers, vortioxetine exposure increases approximately 2-fold; the prescribing information recommends halving the maximum dose in poor metabolizers. Potent CYP2D6 inhibitors such as bupropion, fluoxetine, and paroxetine can increase vortioxetine plasma concentrations substantially, necessitating dose adjustment. Strong CYP inducers such as rifampin reduce vortioxetine exposure by approximately 72%; upward dose adjustment to a maximum of three times the standard dose is recommended in patients on strong inducers. Vortioxetine carries a theoretical serotonin syndrome risk when combined with other serotonergic agents, including MAOIs, and the same washout rules apply as for SSRIs.14
Receptor activities: SERT inhibitor (primary) + 5-HT1A partial agonist + 5-HT1B partial agonist + 5-HT3 antagonist + 5-HT7 antagonist.
Clinical advantages: Reduced nausea vs. SSRIs (5-HT3 antagonism); cognitive benefits in attention, processing speed, executive function (5-HT3 + 5-HT7 mechanisms); favorable sexual dysfunction profile relative to SSRIs; once-daily dosing; long half-life reduces discontinuation syndrome risk.
Key interaction: CYP2D6 substrate; halve dose in poor metabolizers or with potent CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine). Triple dose if on strong CYP inducer (rifampin).
Clinical positioning: Preferred when cognitive dysfunction is a prominent feature of depression; reasonable first-line choice in patients who previously experienced intolerable nausea or sexual dysfunction on SSRIs.
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–1120.
doi:10.1056/NEJMra041867Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010;25(12):1780–1790.
doi:10.1002/mds.23220Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642.
doi:10.1093/qjmed/hcg109Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28(5):205–214.
doi:10.1097/01.wnf.0000177642.49192.59Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185–219.
doi:10.1016/0893-133X(94)00058-8Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855–870.
doi:10.1017/S1092852900016965Brown CS, Bhatta M, Malik C. Monoamine oxidase inhibitor drug interactions and dietary restrictions: guidelines for practice. Expert Opin Drug Saf. 2003;2(5):485–498.
doi:10.1517/14740338.2.5.485Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol. 1993;7(3–4):167–180.
doi:10.1097/00004850-199300730-00008Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346(4):257–270.
doi:10.1056/NEJMra010917Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675.
doi:10.1016/S0140-6736(01)06711-3Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259–1287.
doi:10.2165/00003495-200060060-00003Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64(6):655–660.
doi:10.1016/S0009-9236(98)90056-XRojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1–3):1–7.
doi:10.1016/j.ejphar.2012.01.046Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
doi:10.1016/j.pharmthera.2014.07.001McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567.
doi:10.1017/S1461145714000546